Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

Published:2015-07 Issue:7 Volume:15 Page:775-784
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Perez-Molina José A,Rubio Rafael,Rivero Antonio,Pasquau Juan,Suárez-Lozano Ignacio,Riera Melcior,Estébanez Miriam,Santos Jesús,Sanz-Moreno José,Troya Jesús,Mariño Ana,Antela Antonio,Navarro Jordi,Esteban Herminia,Moreno Santiago

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference41 articles.

1. Guidelines. Version 7.1. November 2014,2014

2. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,2014

3. Adverse effects of antiretroviral therapy;Carr;Lancet,2000

4. Renal toxicity associated with antiretroviral therapy;Calza;HIV Clin Trials,2012

5. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients;Mocroft;AIDS,2010

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes;AIDS;2023-12-11

2. Two-drug antiretroviral regimens for HIV;BMJ;2023-09-01

3. Efficacy and safety of switching lamivudine-based dual therapies for the maintenance of virologic suppression in adults with HIV-1: a systematic review and network meta-analysis;2023-08-17

4. Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting;International Journal of Antimicrobial Agents;2023-08

5. Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction;The Brazilian Journal of Infectious Diseases;2023-05